NASDAQ:ACAD ACADIA Pharmaceuticals Q3 2025 Earnings Report $20.06 -0.57 (-2.76%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$19.98 -0.08 (-0.42%) As of 10/10/2025 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast ACADIA Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS $0.14Beat/MissN/AOne Year Ago EPSN/AACADIA Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$276.52 millionBeat/MissN/AYoY Revenue GrowthN/AACADIA Pharmaceuticals Announcement DetailsQuarterQ3 2025Date11/5/2025TimeBefore Market OpensConference Call DateWednesday, November 5, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile ACADIA Pharmaceuticals Earnings HeadlinesQ4 EPS Estimate for ACADIA Pharmaceuticals Lifted by AnalystOctober 11 at 2:53 AM | americanbankingnews.comLeerink Partnrs Has Negative Outlook for ACAD Q3 EarningsOctober 10 at 2:25 AM | americanbankingnews.comBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging crypto — now called “Wall Street’s preferred choice” — with tech giants like Microsoft, Google, and Amazon already using it.October 12 at 2:00 AM | Weiss Ratings (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACADOctober 8, 2025 | prnewswire.comAcadia Healthcare names Todd Young CFOOctober 7, 2025 | msn.comBrokerages Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Price Target at $29.12October 7, 2025 | americanbankingnews.comSee More ACADIA Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ACADIA Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ACADIA Pharmaceuticals and other key companies, straight to your email. Email Address About ACADIA PharmaceuticalsACADIA Pharmaceuticals (NASDAQ:ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics. The company’s flagship product, NUPLAZID® (pimavanserin), received U.S. Food and Drug Administration approval for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Beyond NUPLAZID, ACADIA is pursuing additional indications for pimavanserin in dementia-related psychosis and Alzheimer’s disease psychosis, as well as exploring novel candidates for schizophrenia and other neuropsychiatric disorders. These efforts are complemented by strategic collaborations, translational research initiatives, and robust clinical trial programs to expand the company’s impact on patient care. ACADIA serves patients and healthcare providers primarily in North America, with ongoing clinical studies and regulatory submissions extending into Europe and Asia-Pacific regions. The company leverages partnerships with academic institutions and industry collaborators to accelerate development timelines and enhance its global footprint. Guided by a leadership team with extensive experience in CNS drug development, ACADIA continues to build on its scientific heritage and commitment to delivering differentiated therapies for complex neurological conditions.View ACADIA Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi Deal Upcoming Earnings Fastenal (10/13/2025)America Movil (10/14/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
